vTv Therapeutics VTVT Stock Price Today

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. VTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally https://1investing.in/ administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program.

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat’s FREE daily newsletter. We’d like to share more about how we work and what drives our day-to-day business. Compare
VTVT’s historical performance
against its industry peers and the overall market. Shares of vTv Therapeutics Inc. plunged in the extended session Monday after the drug developer said a late-stage clinical trial of its Alzheimer’s disease treatment did not meet study goals.

Related Stocks

VTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year.

Cantex is developing azeliragon as a once-a-day pill for the treatment of glioblastoma and other cancers WESTON, Fla. , Feb. 27, 2023 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical-stage pha… VTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreement vTv discovered small molecule RAGE inhibitor depreciation vs amortisation being developed by Cante… VTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreement vTv discovered small molecule RAGE inhibitor is being developed by… Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of VTVT stock can currently be purchased for approximately $0.49.

There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. WESTON, Fla. , Jan. 9, 2023 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening m… WESTON, Fla. , March 6, 2023 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening …

These returns cover a period from January 1, 1988 through July 31, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.

Analyst Forecast

WESTON, Fla. , June 15, 2023 /PRNewswire/ — Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening … You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. According to 1 stock analyst, the rating for VTVT is “Strong Buy”. This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month.

vTv Therapeutics Stock Forecast

According to 1 stock analyst, the 12-month stock price forecast for VTVT stock stock is $6.00, which predicts an increase of 1,121.00%. High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

vTv Therapeutics Inc. (VTVT)

The technique has proven to be very useful for finding positive surprises. According to one analyst, the rating for VTVT stock is “Strong Buy” and the 12-month stock price forecast is $6.0. The scores are based on the trading styles of Value, Growth, and Momentum.

• The technique has proven to be very useful for finding positive surprises.
• According to 1 stock analyst, the 12-month stock price forecast for VTVT stock stock is $6.00, which predicts an increase of 1,121.00%.
• Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year.
• These companies have a low market capitalization and are not yet pr…

This suggests a possible upside of 1,121.0% from the stock’s current price. View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts. 1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for vTv Therapeutics in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “buy” VTVT shares.

Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. (VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel served as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. Cantex’s once daily, orally administered, azeliragon inhibits interactions of the receptor for advanced glycation end products (RAGE) Researchers showed RAGE inhibition to be a potential target for tr… Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet pr…

Investor Services

Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.